Dr. Mauricio Concha, MD
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Years since graduation
- 40
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 864
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
FL license ME69547
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Sarasota Memorial Hospital Sarasota, FL
- Sarasota Memorial Hospital - Venice North Venice, FL
Medical groups
- Intercoastal Medical Group Inc (177 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 864
- Services billed
- 3,435
- Patients’ average age
- 78
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 391 | 291 |
| Ultrasound of both sides of head and neck blood flow | 255 | 253 |
| Insertion of needle into vein for collection of blood sample | 130 | 113 |
| Established patient office or other outpatient visit, 40-54 minutes | 107 | 104 |
| New patient office or other outpatient visit, 60-74 minutes | 106 | 106 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 104 | 103 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 76 | 60 |
| Cyanocobalamin (vitamin b-12) level | 64 | 62 |
| Folic acid level, serum | 56 | 55 |
| Blood test, thyroid stimulating hormone (tsh) | 34 | 34 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 17 companies reported 92 payments worth $48,068 in total to this clinician.
| Lilly USA, LLC | $42,349 |
|---|---|
| Eli Lilly and Company | $2,750 |
| Amgen Inc. | $1,248 |
| AbbVie Inc. | $550 |
| Penumbra, Inc. | $301 |
| Eisai Inc. | $246 |
| Novo Nordisk Inc | $121 |
| Csl Behring | $114 |
| Consulting Fee | $22,513 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $19,425 |
| Travel and Lodging | $3,895 |
| Food and Beverage | $2,236 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Lilly USA, LLC Oct 31, 2025 | Consulting Fee KISUNLA · Neuroscience | $9,375 |
| Lilly USA, LLC Nov 19, 2025 | Consulting FeeCompany’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $8,188 |
| Lilly USA, LLC Sep 8, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $3,125 |
| Eli Lilly and Company May 14, 2025 | Consulting Fee | $2,750 |
| Lilly USA, LLC Oct 24, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $2,500 |
| Lilly USA, LLC Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $2,500 |
| Lilly USA, LLC Oct 14, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $2,500 |
| Lilly USA, LLC Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $2,500 |
| Lilly USA, LLC Oct 31, 2025 | Consulting Fee KISUNLA · Neuroscience | $2,200 |
| Lilly USA, LLC Oct 14, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,250 |
All 28 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Lilly USA, LLC Nov 26, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,250 |
| Lilly USA, LLC Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $2,500 |
| Lilly USA, LLC Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $2,500 |
| Lilly USA, LLC Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $950 |
| Lilly USA, LLC Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $950 |
| Lilly USA, LLC Nov 25, 2025 | Travel and Lodging KISUNLA · Neuroscience · travel to OSPREY, FL | $17.50 |
| Lilly USA, LLC Nov 19, 2025 | Consulting FeeCompany’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $8,188 |
| Lilly USA, LLC Nov 14, 2025 | Travel and Lodging KISUNLA · Neuroscience · travel to BRADENTON, FL | $21.00 |
| Lilly USA, LLC Nov 5, 2025 | Travel and Lodging travel to CANCÚN, Mexico · in-kind | $583 |
| Lilly USA, LLC Nov 5, 2025 | Travel and Lodging travel to CANCÚN, Mexico · in-kind | $479 |
| Lilly USA, LLC Nov 5, 2025 | Travel and Lodging travel to CANCÚN, Mexico · in-kind | $380 |
| Lilly USA, LLC Nov 5, 2025 | Travel and Lodging travel to CANCÚN, Mexico · in-kind | $252 |
| Lilly USA, LLC Oct 31, 2025 | Consulting Fee KISUNLA · Neuroscience | $9,375 |
| Lilly USA, LLC Oct 31, 2025 | Consulting Fee KISUNLA · Neuroscience | $2,200 |
| Lilly USA, LLC Oct 24, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $2,500 |
| Lilly USA, LLC Oct 24, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $950 |
| Lilly USA, LLC Oct 24, 2025 | Travel and Lodging travel to N/A, NC · in-kind | $428 |
| Lilly USA, LLC Oct 24, 2025 | Travel and Lodging travel to N/A, GA · in-kind | $366 |
| Lilly USA, LLC Oct 24, 2025 | Travel and Lodging travel to N/A, FL · in-kind | $231 |
| Lilly USA, LLC Oct 24, 2025 | Travel and Lodging travel to N/A, FL · in-kind | $157 |
| Lilly USA, LLC Oct 14, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $2,500 |
| Lilly USA, LLC Oct 14, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,250 |
| Lilly USA, LLC Oct 14, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $950 |
| Lilly USA, LLC Sep 8, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $3,125 |
| Amgen Inc. Jul 25, 2025 | Travel and Lodging travel to Dallas, TX · in-kind | $36.80 |
| Amgen Inc. Jul 23, 2025 | Travel and Lodging travel to Dallas, TX · in-kind | $567 |
| Amgen Inc. Jul 23, 2025 | Travel and Lodging travel to Dallas, TX · in-kind | $375 |
| Eli Lilly and Company May 14, 2025 | Consulting Fee | $2,750 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 11 industry-funded studies in 2025, from 6 companies. The companies reported $841,781 in research payments for these studies, mostly to the institutions running them.
- Time to Reversal Agents in
AstraZeneca Pharmaceuticals LP - A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease
Eli Lilly and Company · Completed · NCT06538116 - A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (Targe…
E.r. Squibb & Sons, L.l.c. - A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or O…
Amgen Inc. - A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
Eli Lilly and Company · Active, not recruiting · NCT04437511 - Study name not reported
Novo Nordisk As - ITI-1284-201
Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) - A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimer…
E.r. Squibb & Sons, L.l.c. - A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
Amgen Inc. - A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
E.r. Squibb & Sons, L.l.c. · Active, not recruiting · NCT06025578
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.